Comparative Pharmacology
Head-to-head clinical analysis: CYSTEINE HYDROCHLORIDE versus MUCOSIL 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYSTEINE HYDROCHLORIDE versus MUCOSIL 20.
CYSTEINE HYDROCHLORIDE vs MUCOSIL-20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cysteine hydrochloride serves as a precursor to glutathione, an important antioxidant. It also provides a source of cysteine for protein synthesis and acts as a mucolytic agent by reducing disulfide bonds in mucus glycoproteins, thereby decreasing viscosity.
Mucolytic agent that reduces mucus viscosity by breaking disulfide bonds in mucoproteins.
Intravenous: 0.8-1 g/m²/day divided every 6 hours for acetaminophen poisoning; for parenteral nutrition, 0.66-1.7 g of cysteine/kg/day (as hydrochloride).
1200 mg orally twice daily (2400 mg/day) or 600 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life: 1.5-3 hours in adults with normal renal function; prolonged in renal impairment (up to 8-10 hours in severe cases).
Terminal elimination half-life is 5-6 hours in adults with normal renal function. In patients with creatinine clearance <30 mL/min, half-life may extend to 15-20 hours, requiring dose adjustment.
Renal: 40-60% as unchanged drug and metabolites; fecal: <5%; minor biliary elimination; route of administration (e.g., intravenous) influences exact percentages.
Primarily renal: 70-80% of the dose excreted unchanged in urine. Biliary/fecal elimination accounts for less than 10%. Approximately 5% is eliminated as metabolites.
Category C
Category C
Mucolytic
Mucolytic